The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
|Articles|March 17, 2020
Contagion Live News Network: Coronavirus Updates for March 17, 2020
Author(s)Grant M. Gallagher
Stay on top of coronavirus developments from March 17, 2020.
Advertisement
Welcome to the Contagion Live News Network. I’m Grant Gallagher and this is the COVID-19 update for Tuesday, March 17th, 2020.
A new article on Contagion Live highlights how tele-medicine could be a major asset in fighting COVID-19. The practice may allow clinicians to screen more patients and direct them for testing if necessary, while minimizing initial risk for health care workers.
We also now have new information about the first known case of person to person transmission in the United States, based on a study detailing that none of the 347 patient contacts health officials traced in the aftermath tested positive for the virus.
More has also emerged about pediatric cases of COVID-19, after a new study on the lessened severity among children in COVID19 cases seen thus far.
For more on these stories, COVID-19, and the latest infectious disease news, visit ContagionLive.com. To track the spread of coronavirus in the United States and abroad, be sure to use the Contagion Outbreak Monitor.
For the Contagion Live News Network, I’m Grant Gallagher. Take care.
Advertisement
Related to this article
Investigational agent Zelicapavir cut time to complete RSV symptom resolution by up to a week and lowered hospitalization in high-risk adults.
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.
The latest CDC numbers show a 4.0% increase in measles cases from week-to-week, bringing the 2026 US total to 4588 confirmed cases. Ninety-six percent of cases are outbreak-associated.
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.
Oral zelicapavir cut time to complete RSV symptom resolution by up to 1 week in high-risk adults, but it did not meet its primary end point in a phase 2 trial.
The latest CDC numbers show an 8.1% increase in measles cases from week-to-week, bringing the 2026 US total to 4410 confirmed cases. A CDC disease detective is going to Pennsylvania to aid in the state's massive outbreak, and the agency reports on a rare measles complication that is uniformly fatal.
An APP-driven complex outpatient antimicrobial therapy (COpAT) program for patients with bone and joint infections cut mean time to post-discharge follow-up from 20.1 to 9.7 days but did not significantly reduce 30-day readmissions or emergency department visits.
Advertisement
Advertisement
Trending on Contagion Live
1
A Closer Look at IDSA/ESCMID 2026 Consensus Statements 6 and 7 on Staphylococcus aureus Bacteremia
2
Measles Update: October 30, 2026
3
Thinking Outside the IV: Implementation of a COpAT Program for Patients With Bone and Joint Infections
4
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
5